Sampath Reddy discusses market risks in FY25 due to elevated valuations, emphasizing the pharmaceutical sector’s potential. He advises favoring large-caps, notes SEBI’s stress-test for MF schemes, and highlights post-election sector benefits. Reddy also says: “We expect that equity returns maybe a bit subdued in FY25 compared to FY24, even though the long-term India growth story remains intact.”
| Subscribe To Our Free Newsletter |
